Articles tagged with Cytokines
Researchers created implantable beads that produce high concentrations of interleukin-2, a natural compound activating white blood cells to fight cancer. The treatment eradicated ovarian and colorectal cancer in mice within six days, paving the way for human clinical trials later this year.
Researchers have identified how IL-36 cytokines instruct proinflammatory CD4+ T cells to accumulate in the inflamed intestine, worsening disease. This discovery offers fresh insights into targeting these proteins as a new therapeutic option for childhood IBD patients.
The study defines the lung macrophage as a major target of IL-9, which promotes allergic lung inflammation. The researchers found a correlation between IL-9 and the diagnosis of asthma in patients, suggesting a potential therapeutic approach for treatment.
New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.
Researchers found that interleukin-2 promotes the development of two subsets of CD8 T cells, one producing IL-2 and the other not, with distinct fates. The IL-2-producing cells develop into immune memory cells with long-term protection, while the non-IL-2-producing cells gain effector traits but lose memory formation.
Researchers at Gladstone Institutes and UC San Francisco have developed a CRISPR activation method that allows them to activate genes in human immune cells, revealing key regulators of cytokine production. This breakthrough accelerates immunotherapy research and may lead to more powerful cancer treatments.
Scientists at UC Riverside and UCLA have engineered nanoparticles to serve as 'molecular traps' that bind to SARS-CoV-2, preventing it from attacking macrophages and inducing inflammation. The findings suggest potential therapeutic strategies for treating COVID-19-associated diseases.
CERC-002, a cytokine neutralizer, has been shown to improve survival rates by 83.9% among hospitalized COVID patients compared to 64.5% with placebo. The treatment targets the immune response early on, preventing disease progression.
Researchers have discovered a pattern of immune activity in normal pregnancies that can detect abnormalities and predict complications. The study found elevated immune activation in the first three months, followed by a calmer phase, and higher activity in the last three months, especially when childbirth is imminent.
A novel approach may reduce the serious adverse effect of cytokine release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy. Supressing interferon gamma (IFNγ) appears to prevent activation of macrophages and other immune cells that drive the syndrome without impacting CAR T-cell efficacy.
Researchers found fecal transplants increase IL-25, reducing tissue inflammation and boosting immune system response to C. difficile infections. The transplants also promote beneficial microbial diversity, helping patients heal from life-threatening diarrhea.
Scientists from Japan discover IL-36Ra plays a pivotal role in wound healing, and Cl-amidine normalizes exacerbated I/R injury. The study's findings suggest IL-36Ra as a potential therapeutic target for cutaneous I/R injuries.
A new study investigates the effects of cord blood cell transplantation and curcumin administration on Tay-Sachs disease. The results show an increase in enzyme production and a decrease in inflammation after transplantation, as well as improved symptoms and reduced GM2 ganglioside levels when combined with curcumin.
Researchers at Karolinska Institutet discovered that interleukin-26 plays a critical role in bacterial pneumonia by directly killing bacteria and modulating the immune system. This finding positions IL-26 as a new potential target for biological treatment of pneumonia, an increasing global health threat.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
A study in rats found that a diet of highly processed foods led to inflammation and behavioral signs of memory loss in the brain. Supplementing with omega-3 fatty acid DHA prevented these effects almost entirely. The study suggests that limiting processed foods and increasing DHA consumption may help prevent rapid memory decline in old...
Researchers identified a new cell type in human skin contributing to AD and psoriasis, highlighting potential therapeutic targets. The study revealed CD14+ type 3 dendritic cells co-producing IL1B and IL23A, essential for PSO pathogenesis.
A new gene delivery system promotes healing in rat models by preventing inflammation and bone degradation after tooth replantation. The study found that teeth treated with the system showed significantly greater dental root thickness and fewer osteoclasts, leading to improved success rates.
Researchers at UC Berkeley found that tumors release chemicals compromising the blood-brain barrier, leading to inflammation and tissue wasting. Blocking these chemicals could extend life span and improve health for cancer patients, reducing the need for toxic drugs.
A study from Michigan Medicine found that people with type 2 diabetes are more likely to develop a cytokine storm during coronavirus infection due to the enzyme SETDB2. Administering interferon beta increased SETDB2 and decreased inflammatory cytokines in diabetic mice, offering potential therapy for severe COVID-19.
Researchers discovered that cytokine APRIL protects against atherosclerosis by binding to proteoglycans in arteries, reducing plaque formation. High levels of non-canonical APRIL (nc-APRIL) in human blood predict risk of cardiovascular death.
Researchers review advancements in biosensing technologies for neonatal sepsis diagnosis, highlighting the need for faster and more accurate methods. Biosensors offer a promising solution, detecting multiple parameters simultaneously with high sensitivity and accuracy.
The study found that a single-number quantitative measure, the inflammatory-age score, tracks well with a person's immunological response and the likelihood of incurring aging-related diseases. Blood levels of CXCL9, a cytokine secreted by certain immune cells, contribute more powerfully than any other clock component to the inflammato...
A research team at Harvard's Wyss Institute has developed a new approach to treat Duchenne Muscular Dystrophy using nanoparticle-based anti-inflammatory cytokines. Locally applied nanoparticles improve muscle functions and boost the numbers of infiltrating anti-inflammatory regulatory T cells, leading to stronger muscles.
Researchers found that higher levels of pro-inflammatory cytokines, such as IL-12 and IFN-γ, are associated with slower cognitive decline in aging adults with amyloid beta deposits in their brains. Elevated levels of IL-12 were also linked to fewer tau tangles and better brain health outcomes.
Divita Mathur is investigating cytosolic access and instability of DNA nanoparticles to overcome current delivery mechanisms. The goal is to create more biocompatible delivery systems, enabling advanced targeted therapies.
Researchers from the University of Melbourne have identified four specific types of cytokines that cause severe inflammation during influenza virus infection. This allows clinicians to predict whether a patient will become severely ill with influenza, enabling early interventions and improved outcomes.
A groundbreaking study has identified IL-17 cytokine as the primary culprit behind excessive lung inflammation in TB patients. By targeting this pathway, doctors may be able to reduce disease harm and speed up patient recovery.
Research suggests that bradykinin, substance P, and neurotensin may contribute to severe COVID-19 complications through mechanisms involving vascular permeability and cytokine storms. The review aims to bring awareness to these often-overlooked peptides, which may play a crucial role in disease management.
Researchers found four lncRNAs linked to cytokine storms in severe SARS-CoV-2 infection, suggesting potential therapeutic targets. The study sheds light on immune dysfunction mechanisms and informs novel approaches for treating severe COVID-19 patients.
A new sweat sensor can detect elevated pro-inflammatory cytokines in patients with respiratory infections, including COVID-19. The device measures tiny amounts of passive sweat to track cytokine levels, potentially reducing hospitalizations and deaths.
A long-term study found that prenatal exposure to inflammatory substances affects stress circuitry function in male and female offspring, retained into midlife. Abnormal levels of pro-inflammatory cytokines produced in mothers during pregnancy affect brain development differences by sex.
Researchers found that cytokines CCL2 and CCL3 drive lung damage by attracting immune cells, while survivors had higher levels of antiviral T cells, suggesting these cells help control the virus. Targeting these cytokines with inhibitors may prevent lung tissue damage.
Researchers analyzed COVID-19 data to understand the immune system's response and found SARS-CoV-2 uniquely triggers a more severe cytokine storm in certain patients. The study aims to identify better treatments and diagnoses for this deadly condition.
Researchers at WashU Medicine have found a new way to block chronic lung diseases such as asthma and COPD by targeting the packaging of inflammatory cytokines in exosomes. By blocking the release of these packaged cytokines, they can prevent damage to the lungs and slow disease progression in mice.
Researchers developed a novel Biomesh that captures positively charged cytokines, reducing inflammation and tissue adhesion in hernia repair. The new mesh effectively minimized postsurgical complications in an animal model, improving outcomes and reducing symptoms.
Researchers at McMaster University have developed a surface that repels all components of human blood except for the critical cytokine Interleukin-6 (IL-6), which can be measured with high accuracy and sensitivity.
Researchers found that combining Th1 cytokines IFN-gamma and TNF-alpha with the small molecule Akt antagonist MK-2206 maximizes indicators of apoptotic cell death in breast cancer cells. The study also suggests a combined therapy approach for Akt-targeting drugs that incorporates recombinant Interferon-gamma.
Researchers discovered a blood profile that predicts patients at greatest risk of life-threatening immune system overreaction in COVID-19. Combining this cytokine test with clinical assessment could help doctors identify and treat those most at risk.
Researchers at the University of Chicago have designed a new therapy for multiple sclerosis by fusing a cytokine to a blood protein. This combination prevented destructive immune cells from infiltrating the central nervous system and decreased MS development, leading to fewer symptoms and disease prevention.
The study reveals that chitin oligosaccharides trigger cytosolic calcium oscillations, which propagate across the whole plant and synchronize cell responses. This synchronized signal affects transcription of defense-related genes, allowing plants to mount a uniform defense response.
Scientists at The Mount Sinai Hospital have discovered two inflammation markers that reliably predict COVID-19 severity and survival. Elevated levels of IL-6 and TNF-α in serum indicate a higher risk of death, allowing for early stratification and treatment optimization.
Researchers found that COVID-19 patients who experience cytokine storms have a disrupted immune response, leading to the formation of few germinal centers and thus preventing durable immunity. Although some neutralizing antibodies are produced, they lack long-term memory, allowing for repeated infections with the same virus.
Researchers found that COVID-19 patients often lack germinal centers, essential for a durable immune response, due to impaired helper T cell development. This can lead to short-lived immunity and increased risk of re-infection, complicating the development of herd immunity.
Researchers from Children's Hospital of Philadelphia found that patients with Multisystem Inflammatory Syndrome in Children (MIS-C) had elevated levels of IL-10 and TNF-? cytokines, distinguishing them from severe COVID-19. Simple peripheral blood smears also helped distinguish the conditions.
Researchers found that blocking IL-17A increases the presence of other inflammatory molecules produced by Th17 cells, immune cells involved in neuroinflammation. The study suggests a combination approach involving both IL-17A and IL-24 may be more effective in treating autoimmune disorders of the nervous system.
St18 is a negative regulator of VEGF signaling, which plays a critical role in septic pathophysiology. Mice lacking St18 exhibit increased retinal vasculature and enhanced serum VEGF concentrations, highlighting the importance of St18 in regulating VEGF.
A collaboration between University of Toronto and National Jewish Health has yielded a new drug discovery that could combat inflammation and acute respiratory illnesses like COVID-19. The 'drug' is a combination of two naturally occurring peptides, TAT CARMIL1, which reduces collagen degradation by up to 43%.
Researchers found that interleukin-2 is critically important to driving resistance to dexamethasone in HLH. Blocking interleukin-2's effect can re-sensitize T cells to dexamethasone, making the combination of dexamethasone and ruxolitinib a promising treatment for HLH.
Dendritic cells can be labeled using an engineered sugar molecule that is taken up by the cells and displayed on their surfaces, allowing them to track DCs in vivo. The researchers also developed a system to modulate the behavior of DCs via click chemistry, which has great promise for treating cancer and other diseases.
Researchers investigate lopinavir and ritonavir's effectiveness for treating COVID-19, finding current dosing may be ineffective. Cytokine levels are reported in a patient with COVID-19 and acute respiratory distress syndrome, highlighting the potential role of cytokines in disease progression.
Professors Sarah Gaffen and Vijay Kuchroo jointly recognized for deciphering the role of IL-17 in health and disease. Their work has made significant headway in establishing systems for IL-17 investigation, contributing to immunotherapeutics targeting autoimmune diseases.
Researchers at the University of York discovered that mutations in stem cells can cause blood cancer by disrupting normal cell communication. The study used super-resolution microscopy to observe how cells receive instructions from signalling proteins, leading to uncontrolled signals and imbalance in healthy blood cells.
Researchers discovered that exposure to flickering light at 40 Hz causes brains to release signaling chemicals that may help fight Alzheimer's disease. The study found a surge of cytokines and phosphoproteins, which could support neural health and activate microglia to clean up amyloid beta plaques.
Researchers discovered that specific immune T cells from people with ME/CFS exhibit disruptions in energy production, suggesting changes in the immune system. The study found decreased levels of glycolysis and mitochondrial function in affected cells, potentially providing clues to understanding the mechanisms underlying ME/CFS.
MAIT cells play a key role in group A streptococcal toxic shock, producing large amounts of cytokines that cause over-reaction. The discovery has potential implications for diagnosis and treatment of life-threatening conditions.
Researchers have found a novel approach to limit excessive immune responses in chronic diseases like psoriasis, asthma, and HIV by targeting the IL-1 family. The study identifies IL-1R3 as a potential target for effective treatment, offering a new direction for research and therapy.
Researchers develop a technique to confine cytokine treatments to tumors by attaching a collagen-binding protein called lumican. The treatment improves survival rates in mice when combined with immunotherapies, while eliminating toxicity associated with cytokines alone.
Researchers at Rockefeller University developed small molecules that inhibit cGAS, an enzyme implicated in misguided immune responses. These compounds could lead to new treatments for people with certain autoimmune disorders and shed light on autoimmunity.